WST - Earnings announcements

Strong Start to the Year and Raising Full-Year Revenue and EPS guidanceEXTON, Pa., April 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period)Net sales of $844.9 million increased 21.0%; organic growth was 15.3%.Diluted earnings per share ("EPS") of $1.92 increased 56.1%.Adjusted-diluted EPS of $2.13 increased 46.9%.Operating cash flow was $89.9 million. C

EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone partic

– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025. Fourth-Quarter and Full-Year 2025 Summary (comparisons to prior-year period) Fourth-quarter net sales of $805.0 million increased 7.5%; organic growth was 3.3%.Fourth-quarter diluted earnings per sha

EXTON, Pa., Jan. 29, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registe

- Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components -- Strengthened executive leadership team, including recently appointed CFO Robert McMahon -- Increases Full-Year 2025 Revenue and EPS Guidance - EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the third quarter of 2025. Third-Quarter Summary (comparisons to prior-year period)

EXTON, Pa., Oct. 9, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 23, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone partici

- Conference Call Scheduled for 8 a.m. EDT Today - EXTON, Pa., July 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2025 and a fourth-quarter 2025 dividend. Second-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $766.5 million increased 9.2%; organic net sales growth was 6.8%.Diluted EPS of $1.82, compared to $1.51 in the same period last year.Adjusted-diluted EPS of $1.84, compared to $1.52 in the same period last year.Updates full-year 2025 net sales guidance range to $3.

EXTON, Pa., July 8, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 24, 2025, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participa

Bernard J. Birkett Announces Intention to Retire from West, Company Initiates Search for a Successor Shane Campbell Appointed Senior Vice President, Chief Proprietary Segment Officer EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced executive leadership changes as part of its succession planning process. Bernard J. Birkett, Senior Vice President, Chief Financial Officer, informed West of his intention to step down from his current position this ye

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 24, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2025 and declared a third-quarter 2025 dividend. First-Quarter 2025 Summary (comparisons to prior-year period) Net sales of $698.0 million increased 0.4%; organic net sales growth was 2.1%.Reported-diluted EPS of $1.23, compared to $1.55 in the same period last year.Adjusted-diluted EPS of $1.45, compared to $1.56 in the same period last year.The Company is increasing its full yea

EXTON, Pa., April 10, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 24, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone particip

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,

EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 24, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Third-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%.Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.Adjusted-diluted EPS of $1.85, compared to $2.16 in the same period last year.As a result of favorable currency move

EXTON, Pa., Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 24, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website click here. To ask questions on the conference call, participants need to register in advance

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. Second-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $702.1 million declined 6.9%; organic net sales declined 5.9%.Reported-diluted EPS of $1.51, compared to $2.06 in the same period last year.Adjusted-diluted EPS of $1.52, compared to $2.11 in the same period last year. The Company is updating full-year 20

EXTON, Pa., July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking questions t

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%.Reported-diluted EPS of $1.55 declined by 16.2%.Adjusted-diluted EPS of $1.56 declined by 21.2%.The Company is reaffirming full-year 2024 net sales guidance in a range of $3.000 billion

EXTON, Pa., April 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking questions

- Conference Call Scheduled for 9 a.m. EST Today - EXTON, Pa., Feb. 15, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%.Fourth-quarter 2023 reported-diluted EPS of $1.83 grew

EXTON, Pa., Feb. 1, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2023 financial results before the market opens on Thursday, February 15, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call

EXTON, Pa., Oct. 12, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2023 financial results before the market opens on Thursday, October 26, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking ques

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 27, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) Net sales of $753.8 million declined 2.3%; organic net sales declined 2.5%.Reported-diluted EPS of $2.06, compared to $2.48 in the same period last year.Adjusted-diluted EPS of $2.11, compared to $2.47 in the same period last year.The Company is raising full-year 2023

EXTON, Pa., July 13, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2023 financial results before the market opens on Thursday, July 27, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking questi

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 27, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2023 and updated full-year 2023 financial guidance. First-Quarter 2023 Summary (comparisons to prior-year period) Net sales of $716.6 million declined 0.5%; organic sales growth was 2.3%.Reported-diluted EPS of $1.85 declined by 19.2%.Adjusted-diluted EPS of $1.98 declined by 13.9%.The Company is updating full-year 2023 financial guidance of net sales to a new range of $2.965 bill

EXTON, Pa., April 13, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference call by asking quest

- Conference Call Scheduled for 9 a.m. EST Today - EXTON, Pa., Feb. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year period) Fourth-quarter 2022 net sales of $708.7 million declined 3.0%; organic net sales growth was 2.6%. Full-year 2022 net sales of $2.887 billion grew 2.0%; organic net sales growth was 7.7%.Fourth-quarter 2022 reported-diluted EPS of $1.36 d

EXTON, Pa., Feb. 2, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2022 financial results before the market opens on Thursday, February 16, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website here or by clicking here. To participate in the conference ca

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Oct. 27, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2022 and updated full-year 2022 financial guidance. Third-Quarter 2022 Summary (comparisons to prior-year period) Net sales of $686.9 million declined 2.8%; organic net sales growth was 4.3%.Reported-diluted EPS of $1.59 declined 31.2%.Adjusted-diluted EPS of $2.03 declined 1.5%.Company is updating full-year 2022 net sales guidance to a new range of $2.830 billion to $2.840 billion

EXTON, Pa., Oct. 13, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2022 financial results before the market opens on Thursday, October 27, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website https://bit.ly/3cgSM9S or by clicking here.  To participate in the conference

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., July 28, 2022  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2022 and updated full-year 2022 financial guidance. Second-Quarter 2022 Summary (comparisons to prior-year period) Net sales of $771.3 million grew 6.6%; organic net sales growth was 13.1%.Reported-diluted EPS of $2.48, compared to $2.47 in the same period last year.Adjusted-diluted EPS of $2.47, compared to $2.46 in the same period last year.The Company is updating full-year 202

EXTON, Pa., July 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2022 financial results before the market opens on Thursday, July 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live audio-only webcast will be made available via the Company's Investor Relations website https://bit.ly/3cgSM9S or by clicking here.  To participate in the conference ca

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., April 28, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2022 and updated full-year 2022 financial guidance. First-Quarter 2022 Summary (comparisons to prior-year period) Net sales of $720.0 million grew 7.4%; organic sales growth was 11.0%.Reported-diluted EPS of $2.29 increased 15.1%.Adjusted-diluted EPS of $2.30 increased 12.2%.The Company is reaffirming full-year 2022 financial guidance of net sales in a range of $3.050 billion to $

EXTON, Pa., April 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2022 financial results before the market opens on Thursday, April 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 6690124. A live broadcast of the conference call will be avai

EXTON, Pa., Feb. 17, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2021 and introduced full-year 2022 financial guidance. Fourth-Quarter and Full-Year 2021 Summary (comparisons to prior-year period) Fourth-quarter 2021 net sales of $730.8 million grew 26.0%; organic sales growth was 28.3%. Full-year 2021 net sales of $2.832 billion grew 31.9%; organic sales growth was 29.4%. Fourth-quarter 2021 reported-diluted EPS of $1.93 increased 49.6%. Full-year 2021 reported-diluted EPS of $8.

EXTON, Pa., Feb. 3, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2021 financial results before the market opens on Thursday, February 17, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 1986145. A live broadcast of the conference c

EXTON, Pa., Oct. 28, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the third-quarter 2021 and updated full-year 2021 financial guidance. Third-Quarter 2021 Summary (comparisons to prior-year period) Net sales of $706.5 million grew 28.9%; organic sales growth was 27.9%. Reported-diluted EPS of $2.31 increased 112%. Adjusted-diluted EPS of $2.06 increased 79%. Company is raising full-year 2021 net sales guidance to a new range of $2.800 billion to $2.810 billion, compared to a prior range of $2.760 billion to $2.785

EXTON, Pa., Oct. 14, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter 2021 financial results before the market opens on Thursday, October 28, 2021, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 5587559. A live broadcast of the conference call will be ava

EXTON, Pa., July 29, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the second-quarter 2021 and updated full-year 2021 financial guidance. Second-Quarter 2021 Summary (comparisons to prior-year period) Net sales of $723.6 million grew 37.3%; organic sales growth was 30.6%. Reported-diluted EPS of $2.47 increased 104%. Adjusted-diluted EPS of $2.46 increased 97%. Company is raising full-year 2021 net sales guidance to a new range of $2.760 billion to $2.785 billion, compared to a prior range of $2.630 billion to $2.6

EXTON, Pa., April 29, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance. First-Quarter 2021 Summary (comparisons to prior-year period) Net sales of $670.7 million grew 36.5%; organic sales growth was 31.1%. Reported-diluted EPS of $1.99 increased 101%. Adjusted-diluted EPS of $2.05 increased 103%. The Company is raising full-year 2021 net sales guidance to a new range of $2.630 billion to $2.655 billion, compared to a prior range of $2.500 billion to

EXTON, Pa., Feb. 18, 2021 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter, full-year 2020 and introduced full-year 2021 financial guidance. Fourth-Quarter and Full-Year 2020 Summary (comparisons to prior-year period) Fourth-quarter 2020 net sales of $580.2 million grew 23.3%; organic sales growth was 19.8%. Full-year 2020 net sales of $2.147 billion grew 16.7%; organic sales growth was 16.3%. Fourth-quarter 2020 reported-diluted EPS of $1.29 increased 53.6%. Full-year 2020 reported-diluted EPS of $4.57 increased 42.4%. Fourth-quarter 2020 adjusted-diluted EPS of $1.34 increased 63.4%. Full-year 2020 adjusted-dilut